A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCTID	NCT05811351 (View at clinicaltrials.gov)
Description	The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control. (Show More)
Development Status	Active
Indication	Geographic Atrophy
Disease Ontology Term	DOID:10871
Compound Name	JNJ-1887
Compound Description	AAVCAGsCD59
Sponsor	Janssen Research & Development, LLC
Funder Type	Industry
Recruitment Status	Active not recruiting
Enrollment Count	305 (ACTUAL)
Results Posted	Not Available

Target Gene/Variant	CD59
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV2
Editor Type	none
Dose 1	3.56E10 vg/eye
Dose 2	1.071E11 vg/mL
Dose 3	3.56E11 vg/eye
Dose 4
Dose 5

No.of Trial Sites	162
Locations	Hungary,United States,Czechia,United Kingdom,Portugal,Switzerland,Spain,Canada,Netherlands,Sweden,Belgium,Turkey (Türkiye),Denmark,Poland,Italy,Australia,Germany